These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 11365914)

  • 1. Merck discontinues twice-daily dosing of Crixivan.
    Res Initiat Treat Action; 1998 Oct; 4(6):13. PubMed ID: 11365914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twice-a-day Crixivan study discontinued.
    Newsline People AIDS Coalit N Y; 1998; ():31. PubMed ID: 11367502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twice-daily dosing Crixivan study discontinued.
    WORLD; 1998 Oct; (No 90):7. PubMed ID: 11365922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twice-daily Indinavir dosing not recommended.
    Highleyman L
    BETA; 1998 Oct; ():4. PubMed ID: 11365990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twice daily Indinavir trial stopped.
    TreatmentUpdate; 1998 Oct; 10(8):3-4. PubMed ID: 11365875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crixivan warning: keep to three times a day.
    Gilden D
    GMHC Treat Issues; 1998 Sep; 12(9):2. PubMed ID: 11365805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crixivan (Indinavir): three doses daily, not two, in most regimens.
    James JS
    AIDS Treat News; 1998 Oct; (No 304):4-5. PubMed ID: 11365863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No more twice-a-day Crixivan.
    Vazquez E
    Posit Aware; 1998; 9(6):17. PubMed ID: 11366469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
    Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM;
    Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indinavir, nelfinavir -- twice a day?
    TreatmentUpdate; 1998 Apr; 10(2):3-4. PubMed ID: 11365434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saquinavir update.
    Treat Rev; 1997 Aug; (No 25):6. PubMed ID: 11364616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update from the 5th Conference on Retroviruses and Opportunistic Infections.
    Vazquez E
    Posit Aware; 1998; 9(3):21-3. PubMed ID: 11365483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Merck pushes the envelope with once-daily indinavir.
    TreatmentUpdate; 2001; 12(12):8. PubMed ID: 11570096
    [No Abstract]   [Full Text] [Related]  

  • 14. Goodbye, Invirase. Hello, Fortovase.
    Vazquez E
    Posit Aware; 1998; 9(1):45-6. PubMed ID: 11365001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amprenavir: new preparation. Another HIV protease inhibitor: no proven advance.
    Prescrire Int; 2001 Jun; 10(53):70-2. PubMed ID: 11718166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crixivan reduces viral load.
    AIDS Patient Care STDS; 1996 Feb; 10(1):50. PubMed ID: 11361665
    [No Abstract]   [Full Text] [Related]  

  • 18. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
    Boyd MA; Srasuebkul P; Khongphattanayothin M; Ruxrungtham K; Hassink EA; Duncombe CJ; Ubolyam S; Burger DM; Reiss P; Stek M; Lange J; Cooper DA; Phanuphak P
    Antivir Ther; 2006; 11(2):223-32. PubMed ID: 16640103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection.
    Wheat LJ; Farthing C; Cohen C; Pierone G; Lalezari J; Pilson RS; Siemon-Hryczyk P;
    Antivir Ther; 2002 Sep; 7(3):199-209. PubMed ID: 12487388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
    Boyd M; Mootsikapun P; Burger D; Chuenyam T; Ubolyam S; Mahanontharit A; Sangkote J; Bunyaprawit P; Horsakulchai M; Lange J; Cooper D; Phanuphak P; Ruxrungtham K
    Antivir Ther; 2005; 10(2):301-7. PubMed ID: 15865224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.